Sorafenib tosylate novel drug delivery systems: Implications of nanotechnology in both approved and unapproved indications

• প্রধান লেখক: Hrushikesh Raut (Author), Chetana Jadhav (Author), Karishma Shetty (Author), Neha Laxane (Author), Harsh P. Nijhawan (Author), GSN Koteswara Rao (Author), Rajasekhar Reddy Alavala (Author), Garima Joshi (Author), Ch. Niranjan Patro (Author), Govind Soni (Author), Khushwant S. Yadav (Author)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Elsevier, 2022-11-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

The USFDA has approved sorafenib tosylate for the treatment of thyroid cancer, kidney cancer, and hepatocellular carcinoma. Conventional formulations of sorafenib tosylate have challenges of solubility, permeability, side effects, and drug resistance across cancer cells. Targeted cancer therapies ba...